Poster

Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the US

Abstract: Background: Major depressive disorder (MDD) is a debilitating illness in which depressive symptoms may persist after antidepressant treatment. APA guidelines recommend clinician...

08/20/2024

Health Disparities among Patients with Schizophrenia in an Integrated Healthcare System

Abstract: Background: The substantial disease burden of schizophrenia may be accompanied by disparities in diagnosis and treatment, such as with the use of second-generation antipsychotic...

08/20/2024

Sustained Response to Esketamine Nasal Spray in Patients With Treatment-Resistant Depression: Analysis of Long-Term Data from the SUSTAIN-2 Study

Abstract: Background: This post hoc analysis of SUSTAIN-2 (NCT02497287), an open-label, long-term safety and efficacy study of esketamine nasal spray (ESK), assessed sustained response (S...

08/20/2024

Impact of Clinician and Practice Characteristics on Utilization of and Attitudes Toward Long-Acting Injectable Antipsychotics in Schizophrenia: A Survey of US-Practicing Psychiatric Clinicians (DECIDE)

Abstract: Background: Social determinants of health (eg, race/ethnicity, resources) impact quality of care for a number of chronic diseases. Methods: In DECIDE, US-based psychiatric clin...

08/20/2024

The Efficacy and Safety of Esketamine Nasal Spray Versus Quetiapine Extended Release Over 32 Weeks in Patients With Treatment-Resistant Depression: A Subgroup Analysis of the ESCAPE-TRD Study

Abstract: Objective: ESCAPE‑TRD (NCT04338321), a randomized, open-label, rater-blinded, trial demonstrated benefits for esketamine nasal spray (ESK) versus quetiapine extended release (QX...

08/20/2024

Characteristics and Treatment Patterns in Patients with Unresolved Major Depressive Disorder

Abstract: Objective: To describe key characteristics and treatment patterns in patients with unresolved MDD symptoms by leveraging real-world data. Methods: Patients with unresolved MDD...

08/20/2024

Delirium and a History of Alcohol Dependence – What is the Diagnosis?

Abstract: Delirium is not a well-known adverse effect of Vivitrol. This report describes a rare case of delirium involving visual hallucinations and grandiose delusions associated with Vi...

08/20/2024

Differences in Patient and Healthcare Professional Perspectives on the Key Impacts of Tardive Dyskinesia

Abstract: Background: Physical manifestations of tardive dyskinesia (TD) impact daily activities and present a substantial psychosocial burden.

08/20/2024

Dosing and Treatment Patterns of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...

08/20/2024

Drug-Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved in the US for treatment of adults with tardive dyskinesia (TD). Valbenaz...

08/20/2024